|
| 28838971 | A Loss-of-Function Splice Acceptor Variant in <i>IGF2</i> Is Protective for Type 2 Diabetes. | Diabetes | 2017 |
| 27740516 | Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. | Ann Hepatol | 2016 |
| 26802147 | A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. | Annals of Oncology | 2016 |
| 26957110 | GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. | Journal of Viral Hepatitis | 2016 |
| 27207650 | Genome-wide association study of colorectal cancer in Hispanics. | Carcinogenesis | 2016 |
| 27486033 | Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. | Gastroenterology | 2016 |
| 26473667 | Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. | Liver International | 2016 |
| 25105516 | Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C. | Antivir Ther | 2015 |
| 25622055 | Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV. | Journal of acquired immune deficiency syndromes (1999) | 2015 |
| 26183611 | A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. | Journal of Viral Hepatitis | 2015 |
| 26125013 | Episensitization: Defying Time's Arrow. | Frontiers in Oncology | 2015 |
| 25246359 | Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. | Journal of Infection | 2015 |
| 25080450 | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. | Gut | 2015 |
| 25064437 | A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. | J Hepatol | 2014 |
| 24126097 | Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. | Gastroenterology | 2014 |
| 24120953 | Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. | Clinical Gastroenterology and Hepatology | 2014 |
| 24444658 | Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. | Journal of Hepatology | 2014 |
| 24107072 | A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected | Liver International | 2014 |
| 24251988 | In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions. | Liver International | 2014 |
| 24428467 | Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. | N Engl J Med | 2014 |
| 24184132 | Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. | Gastroenterology | 2014 |
| 24501005 | All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. | Hepatology | 2014 |
| 24464551 | Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. | Antiviral Therapy | 2014 |
| 24915262 | Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. | JAMA | 2014 |
| 25038354 | Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. | JAMA | 2014 |
| 25218783 | Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. | Antiviral Research | 2014 |
| 24907384 | Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. | J Infect Dis | 2014 |
| 24886709 | Amerindian-specific regions under positive selection harbour new lipid variants in Latinos. | Nat Commun | 2014 |
| 24927607 | A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. | Annals of Hepatology | 2014 |
| 25078309 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. | Lancet | 2014 |
| 23242341 | Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. | Current Opinion in Infectious Diseases | 2013 |
| 22951527 | Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein. | J Clin Gastroenterol | 2013 |
| 24215243 | Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. | Expert Review of Anti-Infective Therapy | 2013 |
| 24010644 | All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). | Journal of Viral Hepatitis | 2013 |
| 23534542 | Treatment of HCV infection by targeting microRNA. | New England Journal of Medicine | 2013 |
| 23439259 | A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. | Journal of Hepatology | 2013 |
| 23047118 | A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients. | Antiviral Therapy | 2013 |
| 23348636 | PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. | Hepatology | 2013 |
| 23183528 | Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. | Journal of Hepatology | 2013 |
| 23263000 | Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. | Antimicrobial Agents and Chemotherapy | 2013 |
| 23129048 | Genotypic and phenotypic analyses of hepatitis C virus from patients treated with JTK-853 in a three-day monotherapy. | Antimicrobial Agents and Chemotherapy | 2013 |
| 23499158 | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. | Lancet Infect Dis | 2013 |
| 23607593 | Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. | N Engl J Med | 2013 |
| 23607594 | Sofosbuvir for previously untreated chronic hepatitis C infection. | N Engl J Med | 2013 |
| 21873466 | Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. | Gut | 2012 |
| 22706730 | High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. | Hepatology | 2012 |
| 22306586 | The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV. | HIV Clin Trials | 2012 |
| 22592094 | Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. | HIV Clin Trials | 2012 |
| 22700626 | Â Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients. | Annals of Hepatology | 2012 |
| 22473713 | Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study. | Hepatology | 2012 |